Evogene Receives Nasdaq Minimum Bid Price Notice, Faces September Compliance Deadline
Evogene’s closing bid price fell below $1.00 for 30 consecutive business days, triggering a Nasdaq deficiency notice requiring $1.00 or higher for ten straight trading days by September 28, 2026 to avoid delisting. The company may seek a reverse stock split or extended 180-day cure period if initial compliance fails.
1. Nasdaq Notification and Deadline
Evogene received a Nasdaq notice after its closing bid price remained below $1.00 for 30 consecutive business days, placing it out of compliance with Nasdaq Rule 5550(a)(2). The notice grants the company 180 calendar days—until September 28, 2026—to restore a closing bid of at least $1.00 for ten successive business days or face delisting.
2. Potential Remedies and Continued Listing
To regain compliance, Evogene may implement a reverse stock split or other measures and, if necessary, request a second 180-day cure period provided its market value of publicly held shares and other listing standards are met. Trading on Nasdaq and the Tel Aviv Stock Exchange will continue uninterrupted during the cure periods.